Table 2.

Univariate cox regression analysis of clinical indicators to predict risk of disease progression.

	N	HR	(95% CI)	p value
Age
<65	51 (69.9%)	1
≥65	22 (30.1%)	0.7	(0.4, 1.3)	0.247
Sex
female	18 (24.7%)	1
male	55 (75.3%)	1.1	(0.6, 2.1)	0.69
Smoking History
never	31 (42.5%)	1
ever	42 (57.5%)	0.7	(0.4, 1.2)	0.148
ECOG-PS
<2	65 (89.0%)	1
≥2	8 (11.0%)	0.9	(0.3, 2.2)	0.767
Pathological Type
adenocarcinoma	48 (65.8%)	1
squamous cell carcinoma	20 (27.4%)	0.8	(0.4, 1.4)	0.412
others	2 (5.60%)	1	(0.3, 2.8)	0.961
Brain Metastasis
no	54 (74.0%)	1
yes	19 (26.0%)	1.8	(1.0, 3.3)	0.045
Liver Metastasis
no	57 (78.1%)	1
yes	16 (21.9%)	1.5	(0.8, 2.8)	0.169
Bone Metastasis
no	51 (69.9%)	1
yes	22 (30.1%)	1.3	(0.7, 2.3)	0.364
Lung Metastasis
no	48 (65.8%)	1
yes	25 (34.2%)	1.3	(0.8, 2.3)	0.314
Adrenal Metastasis
no	59 (80.8%)	1
yes	14 (19.2%)	1.1	(0.6, 2.2)	0.774
Line of treatment
2	39 (53.4%)	1
>2	34 (46.6%)	1.2	(0.7, 2.1)	0.453
Stage
III	10 (13.7%)	1
IV	63 (86.3%)	1.5	(0.7, 3.6)	0.32
EGFR mutation
negative	37 (50.7%)	1
positive	16 (21.9%)	1.2	(0.7, 3.6)	0.523
unknown	20 (27.4%)	0.5	(0.3, 1.0)	0.061
PD-L1 TPS
<1%	7 (9.60%)	1
≥1%	10 (13.7%)	1.8	(0.7, 4.8)	0.229
unknown	56 (76.7%)	0.7	(0.3, 1.5)	0.362
Treatment
PC group	36 (49.3%)	1
PA group	27 (37.0%)	0.3	(0.2, 0.6)	<0.001
PAC group	10 (13.7%)	0.5	(0.2, 1.1)	0.071

HR, Hazard Ratio; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; EGFR, Epidermal Growth Factor Receptor; PD-L1 TPS, Programmed Cell Death-Ligand 1 Tumor cell Proportion Score.

PC group: PD-1/PD-L1 inhibitors plus Chemotherapy.

PA group: PD-1/PD-L1 inhibitors plus anti-angiogenic agents.

PAC group: PD-1/PD-L1 inhibitors plus anti-angiogenic agents plus Chemotherapy.